✦ LIBER ✦

Genetic polymorphisms ofCYP2D6increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy

✍ Scribed by Damodaran, Solai Elango; Pradhan, Suresh Chandra; Umamaheswaran, Gurusamy; Kadambari, Dharanipragada; Reddy, K. Sathyanarayana; Adithan, Chandrasekaran

Book ID: 113028111
Publisher: Springer
Year: 2012
Tongue: English
Weight: 266 KB
Volume: 70
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-012-1891-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Risk of Recurrence in Breast Cancer

The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms ofCYP2D6andABCB1

✍ L. K. Teh; N. I. Mohamed; M. Z. Salleh; M. Rohaizak; N. S. Shahrun; J. J. Saladi 📂 Article 📅 2011 🏛 American Association of Pharmaceutical Scientists 🌐 English ⚖ 266 KB

Impact of CYP2D6*10 on recurrence-free s

Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy

✍ Kazuma Kiyotani; Taisei Mushiroda; Mitsunori Sasa; Yoshimi Bando; Ikuko Sumitomo 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB

Comment on ‘Impact of CYP2D6*10 on recur

Comment on ‘Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy’

✍ Timothy L. Lash; Thomas P. Ahern; Deirdre Cronin-Fenton; Jens Peter Garne; Steph 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB

Significant Effect of Polymorphisms in C

Significant Effect of Polymorphisms in CYP2D6 and ABCC2 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients

✍ Kiyotani, K.; Mushiroda, T.; Imamura, C. K.; Hosono, N.; Tsunoda, T.; Kubo, M.; 📂 Article 📅 2010 🏛 American Society of Clinical Oncology 🌐 English ⚖ 256 KB

Prognostic factors of early distant recu

Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy : Results of a retrospective analysis

✍ Marc Debled; Gaëtan MacGrogan; Véronique Brouste; Simone Mathoulin-Pelissier; Mi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 1 views

## Abstract ## BACKGROUND Current adjuvant hormone therapy in postmenopausal women with breast cancer is debatable between upfront aromatase inhibitors (AIs) and sequential treatment with tamoxifen. A major concern is the higher rate of early recurrences observed with sequential treatment. The aut

Comparative analysis of breast cancer re

Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of ‘cures’

✍ Romano Demicheli; Rosalba Miceli; Cristina Brambilla; Laura Ferrari; Angela Moli 📂 Article 📅 1999 🏛 Springer US 🌐 English ⚖ 52 KB